That’s the Cherohala Skyway – North Carolina’s best-kept secret that stretches 43 miles of pure scenic bliss from Robbinsville, NC, to Tellico Plains, TN.

Enter the Cherohala Skyway, a 43-mile scenic route connecting Robbinsville, North Carolina to Tellico Plains, Tennessee that delivers mountain majesty without the crowds, inflated prices, or ...

“This year, we’re going to have less trail work done on the trails, so just know that going into your hike, safety is the most important thing,” Kipperman told a group of backpackers from Europe and ...

Snow-covered area in March across the western United States was 8 percent below average, ranking seventeenth in the 25-year satellite record. Snow cover duration was just above the twenty-fifth ...

If you're seeking challenging hiking opportunities in national parks, we've handpicked strenuous trails on varying landscapes ...

The city of Reno, Nevada, is breaking records in ways it doesn't like: A 2024 analysis of 241 cities showed that Reno has ...

Mount Washington, the highest peak in the northeastern United States, is renowned for its extreme weather conditions. This summit experiences winds exceeding hurricane force more than 100 days ...

Pollen counts are expected to be higher than average in 39 states, predicts Alan Reppert ... AccuWeather put together three maps showing when common allergens are expected to peak across the ...

On Friday, Elevation Oncology shares faced a significant ... The stock, currently trading at $0.28, has fallen nearly 95% from its 52-week high of $5.83. According to InvestingPro analysis ...

In this video, we’ll show you how you can unlock the Happy Place trophy or achievement, which requires you to reach the highest point on the map, in Assassin’s Creed Shadows.

Languages: English As President Donald Trump plans to dismantle the Department of Education via an executive order, states are preparing for potential funding cuts to their K-12 schools.

Investing.com -- Shares of Elevation Oncology , Inc. (NASDAQ:ELEV) fell by 20% following the announcement that the company will discontinue the development of its drug candidate EO-3021.